Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by ChromaDex Corporation

< Previous 1 2 3 Next >
ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex to Present at the 37th Annual Roth Conference
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 4, 2025
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex’s Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology’s Inaugural Longevity Supplement
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Corporation Reports Third Quarter 2024 Financial Results
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex to Participate in the 17th Annual LD Micro Main Event
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN)
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Appoints Ozan Pamir as Chief Financial Officer
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Corporation Reports Second Quarter 2024 Financial Results
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex to Present at Canaccord Genuity’s 44th Annual Growth Conference
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs)
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex to Join Russell 2000® Index
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD)
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, June 11, 2024
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.